From diligence to verification: the emergence of the TechBio-Investor.

Recent technical advances, including AI co-scientists and agentic systems, increasingly allow TechBios to undertake scientific verification at scale. In addition to facilitating internal discovery efforts, these capabilities can also be used for making external investment decisions. The emerging synergies between discovery and investment enable a new type of hybrid entity, the TechBio-Investor, which has the potential to reshape the economics and ethics of biotech investing. Scaled verification can help improve capital allocation, steering investment toward stronger science and, in a sector where most drugs fail, conserving resources. The same capabilities also carry risks, including the uneven distribution of benefits and the conflicts faced by TechBio-Investors that compete with, invest in and bet against rivals.